血清KL-6水平与NSCLC患者PD-1相关免疫性肺炎的关联性  

Correlation between serum KL-6 level and PD-1 associated immune pneumonia in patients with NSCLC

作　　者：胡少博 张娜莉[1] 程静梅 Hu Shaobo;Zhang Nali;Cheng Jingmei(Department of Respiratory and Critical Care Medicine,Luoyang Central Hospital,Luoyang 471000,China)

机构地区：[1]洛阳市中心医院呼吸与危重症医学科,洛阳471000

出　　处：《国际医药卫生导报》2024年第4期602-605,共4页International Medicine and Health Guidance News

基　　金：河南省医学科技攻关联合共建项目(LHGJ20220936)。

摘　　要：目的分析血清涎液化糖链抗原-6(KL-6)水平与非小细胞肺癌(NSCLC)患者程序性死亡受体-1(PD-1)相关免疫性肺炎的关联性。方法选择2021年1月至2022年12月就诊于洛阳市中心医院的72例NSCLC患者,其中男43例,女29例;年龄63~75(68.54±3.83)岁;采用PD-1抑制剂治疗1个月。检测患者治疗前、治疗1个月后的血清KL-6水平;观察患者治疗结束后3个月PD-1相关免疫性肺炎发生情况,并根据该疾病发生情况将患者分为发生组与未发生组;比较患者发生PD-1相关免疫性肺炎与治疗前、后血清KL-6水平的关系。采用t检验、χ^(2)检验、点二列相关性分析。结果患者经PD-1抑制剂治疗后,发生相关免疫性肺炎5例,发生率为6.94%(5/72);发生组治疗前、治疗后的血清KL-6水平分别为(1518.72±263.67)U/ml、(1185.36±207.15)U/ml,均高于未发生组(1064.01±185.09)U/ml、(879.44±112.06)U/ml,差异均有统计学意义(均P<0.05);经点二列相关性分析,PD-1相关免疫性肺炎发生情况与治疗前、治疗后血清KL-6水平均呈正相关(r=0.524、0.551,均P<0.001)。结论在PD-1抑制剂治疗过程中,PD-1相关免疫性肺炎发生与治疗前、后血清KL-6水平呈正相关,治疗前血清KL-6水平较高者在治疗后更容易发生相关免疫性肺炎。Objective To analyze the relationship between serum Krebs Von den Lungen-6(KL-6)level and programmed death receptor-1(PD-1)associated immune pneumonia in patients with non-small cell lung cancer(NSCLC).Methods A total of 72 patients with NSCLC admitted to Luoyang Central Hospital from January 2021 to December 2022 were selected,who were treated with PD-1 inhibitor for 1 month.There were 43 males and 29 females,aged 63-75(68.54±3.83)years.Serum KL-6 level was detected before and after 1 month of treatment.The occurrence of PD-1 associated immune pneumonia was observed within 3 months after treatment,and the relationship between the occurrence of PD-1 associated immune pneumonia and serum KL-6 level before and after treatment was compared.t test,χ^(2) test,and point two-column correlation analysis were used.Results After the patients were treated with PD-1 inhibitor,5 cases developed associated immune pneumonia,with an incidence of 6.94%.The serum KL-6 level in the occurrence group was(1518.72±263.67)U/ml before treatment and(1185.36±207.15)U/ml after treatment,which were higher than those in the non-occurrence group[(1064.01±185.09)U/ml and(879.44±112.06)U/ml],with statistically significant differences(both P<0.05).By point two-column correlation analysis,the occurrence of PD-1 associated immune pneumonia was positively correlated with serum KL-6 level before and after treatment(r=0.524 and 0.551,both P<0.001).Conclusion During PD-1 inhibitor therapy,the occurrence of PD-1 associated immune pneumonia is positively correlated with pre-and post-treatment serum KL-6 levels,and patients with higher serum KL-6 level before treatment are more likely to develop associated immune pneumonia after treatment.

关 键 词：非小细胞肺癌 涎液化糖链抗原-6 PD-1抑制剂 免疫性肺炎 

分 类 号：R734.2[医药卫生—肿瘤]